Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 535Carboplatin 533Cisplatin 480pembrolizumab 457Gemcitabine 422Docetaxel 416Rituximab 386Radiotherapy 373Dexamethasone 352Doxorubicin 330Nivolumab 309Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × MM-111 × Clear all
NCT00911898 2015-01-13

Monotherapy

Merrimack Pharmaceuticals

Phase 1 Completed
20 enrolled 5 charts
Breast

Breast Neoplasms

NCT01097460 2015-01-07

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
16 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡